A Study of Obexelimab in Patients With Warm Autoimmune Hemolytic Anemia (SApHiAre)
Study sponsor: Zenas BioPharma (USA), LLC
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2026-06-30Estimated
Enrollment · participants134Estimated
Source updated2025-06-25Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.